Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination With the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Relapsed Or Refractory AML

NCT02249091 is registered in ClinicalTrials.gov with GSO Global Clinical Research BV as lead sponsor.

NCT NCT02249091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02249091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination With the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Relapsed Or Refractory AML
Lead sponsor
GSO Global Clinical Research BV
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2014
Completion date
July 31, 2018
Enrollment
42 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (relapsed/refractory)